Brentuximab vedotin - Seattle Genetics/Takeda

Drug Profile

Brentuximab vedotin - Seattle Genetics/Takeda

Alternative Names: Adcetris; Anti-CD30-MMAE; Anti-CD30-monoclonal-antibody-cAC10-auristatin-E-conjugate; Auristatin-E-anti-CD30-monoclonal-antibody-cAC10-conjugate; cAC10-vcMMAE; MMAE-anti-CD30; SGN-35

Latest Information Update: 17 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Seattle Genetics; Stanford University
  • Developer Bristol-Myers Squibb; Celgene Corporation; Dana-Farber Cancer Institute; Fondazione Italiana Linfomi; Fox Chase Cancer Center; Immune Tolerance Network; Lymphoma Academic Research Organisation; Massachusetts General Hospital; National Cancer Institute (USA); National Institute of Allergy and Infectious Diseases; Seattle Genetics; Stanford University; Takeda; Takeda Oncology; UNC Lineberger Comprehensive Cancer Center
  • Class Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hodgkin's disease; Non-Hodgkin's lymphoma; Anaplastic large cell lymphoma; Peripheral T-cell lymphoma; Cutaneous T cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaplastic large cell lymphoma; Cutaneous T cell lymphoma; Hodgkin's disease; Mycosis fungoides
  • Phase III T cell lymphoma
  • Phase II Adult T-cell leukaemia-lymphoma; Diffuse large B cell lymphoma; Germ cell and embryonal neoplasms; Mastocytosis; Mesothelioma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; Sezary syndrome
  • Phase I/II Diffuse scleroderma
  • Phase I Graft-versus-host disease
  • Discontinued Leukaemia; Multiple myeloma; Solid tumours; Systemic lupus erythematosus

Most Recent Events

  • 03 Jul 2018 Takeda completes enrolment in its phase I/II trial for Hodgkin's Lymphoma in Spain (NCT03576378)
  • 04 Jun 2018 Additional efficacy and adverse events data from the phase III ECHELON-1 trial in Hodgkin's lymphoma released by Seattle Genetics
  • 04 Jun 2018 Long term follow up efficacy and adverse events data from a phase II trial in Hodgkin's Lymphoma released by Seattle Genetics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top